Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase ...

Less than a quarter of patients diagnosed with mild psoriasis had a body surface area of less than 3% at the time of diagnosis.

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

All skin cancers occurring after initiation of phototherapy were included. Records for 3,506 patients were reviewed. Most patients had psoriasis (60.9%) or eczema (26.4%). The median number of ...

Mar. 3, 2025 — Psoriasis is one of the most common chronic ... Jan. 27, 2025 — Basal cell carcinomas, the most common form of skin cancer, occur in chronically sun-exposed areas such as ...

The following is a summary of “Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1,” published in the March 2025 issue of ...

Some evidence suggests a higher risk of liver disease with psoriasis ... to rule out cancer or other conditions. If you haven’t received an official diagnosis for your skin condition, a ...

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...